Elexacaftor-tezacaftor-ivacaftor降低囊性纤维化患者鼻窦微生物组中假单胞菌丰度
本研究在囊性纤维化(CF)患者开始使用elexacaftor-tezacaftor-ivacaftor(ETI)前后采集鼻窦样本,行16S扩增子测序。基线29例样本以葡萄球菌属为主,α多样性低于已发表的無鼻窦疾病参考集。ETI中位治疗9个月后α和β多样性无变化,但基线含假单胞菌属的样本中假单胞菌属及含伯克霍尔德菌属的菌属减少,qPCR证实假单胞菌丰度下降。
要点
- CF患者基线鼻窦微生物组以葡萄球菌属为主,α多样性低于無鼻窦疾病参考集。
- ETI中位治疗9个月后α和β多样性无变化。
- 基线含假单胞菌的样本经ETI后假单胞菌丰度下降,qPCR证实。
核心结论
- ETI治疗使基线存在假单胞菌的个体鼻窦微生物组中假单胞菌属丰度降低。
研究设计与样本
- 在内镜下采集开始ETI前后的鼻窦样本,行16S扩增子测序,序列经QIIME2流程处理并用vegan R包分析。
- 基线样本29例,ETI前后配对样本23对。
主要发现
- 基线时队列样本以葡萄球菌属为主,α多样性低于已发表的無鼻窦疾病个体参考集。
- 有鼻窦手术史者α多样性较低,以Shannon指数、Observed Richness和Faith系统发育多样性指数衡量。
- 有无变应性鼻炎者之间β多样性不同,有变应性鼻炎者葡萄球菌属丰度较高。
- ETI中位治疗9个月后α和β多样性无变化。
- ETI治疗后基线含假单胞菌属和含伯克霍尔德菌属的样本中相应菌属减少,qPCR测得假单胞菌丰度下降;核心成员葡萄球菌属、棒状杆菌属和链球菌属无变化,莫拉菌属增加。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis (CRS) is common in individuals with cystic fibrosis (CF) and is marked by chronic inflammation and episodes of infection that negatively impact quality of life. Several studies have shown that elexacaftor-tezacaftor-ivacaftor (ETI) improves symptoms and examination findings in CF-CRS. The current study determines the effect of ETI on the sinonasal microbiota in CF. METHODS: Sinonasal samples were collected under endoscopic visualization before and after starting ETI. Samples were subjected to 16S amplicon sequencing and sequences were processed with the QIIME2 pipeline with subsequent analysis using the vegan R-package. RESULTS: Twenty-nine individual baseline samples and 23 sample pairs pre-/post-ETI were available. At baseline, the cohort had samples dominated by Staphylococcus, and alpha diversity was lower than that of a published reference set of individuals without sinonasal disease. Individuals with prior sinus surgery had lower alpha diversity as measured by Shannon Index, Observed Richness, and Faith's phylogenetic diversity Index. Beta diversity differed between individuals with and without allergic rhinitis, with higher Staphylococcus abundance in those with allergic rhinitis. No change in alpha or beta diversity was seen after a median of 9 months on ETI. With ETI, the Pseudomonas genus and the genus containing Burkholderia decreased in samples containing these taxa at baseline. Pseudomonas abundance decreased with treatment as measured by qPCR. Core sinonasal microbiome members Staphylococcus, Corynebacterium, and Streptococcus were unchanged, while Moraxella increased with ETI. CONCLUSIONS: Treatment with ETI leads to a reduction in Pseudomonas abundance within the sinonasal microbiome of individuals with Pseudomonas at baseline.
引用
- Zemke AC, Hilliam Y, Stapleton AL, et al. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis. Int Forum Allergy Rhinol. 2023. PMID: 37837613. doi:10.1002/alr.23288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。